S'abonner

The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time - 16/05/17

Doi : 10.1016/j.ahj.2017.01.007 
Chingping Wan, MD, MSHCPM a, , Steven J. Szymkiewicz, MD a, Helmut U. Klein, MD b
a ZOLL, Pittsburgh, PA 
b University of Rochester Medical Center, Heart Research Follow up Program, Rochester, NY 

Reprint requests: Chingping Wan, MD, MSHCPM, ZOLL, 121 Gamma Drive, Pittsburgh, PA, 15238.ZOLL121 Gamma DrivePittsburghPA15238

Abstract

Background

The impact of body mass index (BMI) on the shock efficacy and patient adherence among patients using a wearable cardioverter defibrillator (WCD) is unknown.

Methods

Patients prescribed the WCD between January 1, 2008 and June 1, 2013, who experienced at least one episode of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and who received appropriate WCD therapy, were identified within a registry maintained by the manufacturer for regulatory, reimbursement, and administrative purposes. The registry contained patients' Body Mass Index (BMI) which was categorized as normal (18.0<BMI<25.0), overweight (25.0BMI<30.0) or obese (30.0BMI). Demographics, indication for WCD prescription and other clinical information were reviewed. Device-stored ECG, transthoracic impedance (TTI) and time worn were downloaded for analyses. A post-shock rhythm which was no longer VT or VF was considered a successful tachyarrhythmia conversion. Only the first-shock arrhythmia conversion and TTI were included in the analyses.

Results

A total of 574 patients were included in the final analyses. Patient characteristics were similar across all groups except the obese group (60±11 years) was younger than the normal (63±16 years) and overweight (64±12 years, P=.001) groups. Mean length of use for normal, overweight and obese groups was 79±131, 82±202 and 55±97 days (P=.12), respectively; the median daily wear time was 21 hours among all groups. In a total of 623 VT/VF events, the median TTI was 44 ohms, 51 ohms and 65 ohms for normal, overweight and obese groups, respectively; TTI was positively correlated to BMI (r=0.33, P<.01). First-shock conversion rate was 92.9% in the normal group, 93.6% and 93.9% in the overweight and obese groups, respectively (P=.93). There was no difference in 24-hour survival among the three groups (91.9%, 94.1% and 92.3%, P=.66).

Conclusion

The WCD first-shock success rate and post-event 24-hour survival were high and independent from BMI. TTI was positively correlated with BMI but did not impact early clinical outcome. WCD was safe to all BMI groups and the patient wear time was excellent across all groups.

Le texte complet de cet article est disponible en PDF.

Plan


 Disclosures & Author Contribution: Drs Wan and Szymkiewicz are employees of ZOLL. Dr Klein does not have conflicts.
ECG review and data analysis were conducted initially by physicians from the company (C.W. and S.J.S.) and then were independently verified and approved by physician from University of Rochester (H.U.K.). All authors jointly wrote the manuscript, following the best practice. All authors have approved the final article.


© 2017  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 186

P. 111-117 - avril 2017 Retour au numéro
Article précédent Article précédent
  • Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes
  • Gregory Ducrocq, Phillip J. Schulte, Andrzej Budaj, Jan H. Cornel, Claes Held, Anders Himmelmann, Steen Husted, Robert F. Storey, Christopher P. Cannon, Richard C. Becker, Stefan K. James, Hugo A. Katus, Renato D. Lopes, Emmanuel Sorbets, Lars Wallentin, Philippe Gabriel Steg
| Article suivant Article suivant
  • Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics
  • Edward L. Hannan, Ye Zhong, Alice K. Jacobs, Frederick S.K. Ling, Peter B. Berger, Gary Walford, Ferdinand J. Venditti, Spencer B. King

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.